Navigation Links
Tafamidis: Approval denotes proven added benefit
Date:4/5/2012

This release is available in German.

Tafamidis meglumine (trade name: Vyndaqel) was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder ("orphan disease") is caused by a defective gene and is associated with progressive nerve damage (neurological degeneration) that tafamidis is supposed to delay. According to 35a SGB (Social Code Book) V, an added benefit is regarded as proven if a drug for a rare disease - known as an orphan drug - has been approved. The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed tafamidis at the request of the Federal Joint Committee (G-BA).

The scientific assessment by IQWiG has produced a hint of a positive effect of tafamidis on neurological degeneration.

Tafamidis compared with "best supportive care"

Transthyretin (TTR) is formed in the liver and is involved in the transport of the thyroid hormone, thyroxine. Mutations in the TTR gene can lead to transthyretin amyloidosis in which there is a build-up of an abnormally modified protein in various organs. These insoluble deposits result in a chronic disease that is associated with the progressive degeneration of the nervous system (polyneuropathy). In most patients, the transthyretin gene is modified at a particular site and this mutation is called "Val30Met". Tafamidis meglumine is approved for the treatment of transthyretin amyloidosis in adult patients with stage 1 neurological disorders to delay the progression of degeneration of peripheral nerves, e.g. in the arms and legs.

Treatment with tafamidis combined with "best supportive care" was compared with "best supportive care" alone. The term "best supportive care" means the therapy that provides the patient with the best possible individually optimized supportive treatment to alleviate symptoms and imp
'/>"/>

Contact: Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Neuralstems NSI-189 trial in major depressive disorder receives FDA approval to advance to Phase Ib
2. FDA Revokes Approval of Avastin for Breast Cancer
3. St. Michaels echocardiology lab awarded international seal of approval
4. Mayo Clinic receives FDA approval for ovarian and breast cancer vaccines
5. Pioneering stem cell bandage receives approval for clinical trial
6. FDA predictability a top concern for medtech firms; EU preferred for product approval
7. New Hepatitis C Drugs Close to Gaining FDA Approval
8. New Hepatitis C Drug Close to Gaining FDA Approval
9. Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants
10. FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool
11. Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... , ... Next weekend is Labor Day weekend, the last bash of the ... this year). For IT security personnel, it should also mark the perfect time to ... costly than a simple headache. , Joe Caruso, founder and CEO-CTO of Global ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced today ... and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. ... (VHS) in the United States District Court for the Southern District of Texas ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
(Date:8/28/2015)... ... 28, 2015 , ... “ Frequentz ” was featured on NewsWatch as part ... on the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch ... allows businesses to track product movement from beginning to end. , Businesses benefit greatly ...
Breaking Medicine News(10 mins):Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... the new central clearing house for an ambitious ongoing ... of biomedical data to make it more accessible to ... Resources, a component institute of the National Institutes of ... support the Biomedical Informatics Research Network Coordinating Center (BIRNCC) ...
... offer hope of better hearing for people who suffer ... the non-profit educational organization Better Hearing Institute (BHI). The ... States and Canada found that six out of ten ... hearing aids and two of ten reported major relief. ...
... for surrogates enrolling loved ones in research studies , , ... support having their family members enroll them in disease ... decision themselves, a new study says. , ... would prove especially helpful in studying people with Alzheimer,s ...
... Jan. 21 Health Integrated, a pioneer in targeted ... has joined the fast-growing company as Senior Vice President ... Health Integrated,s Solutions Group which will extend on the ... customers, their members, and network of providers. "Vic is ...
... between tobacco smoke and cancer deaths beyond lung ... study from a UC Davis researcher, suggesting that increased ... estimated. , The epidemiological analysis, published online in ... percent of the cancer death burden among Massachusetts men ...
... 21 Nu Skin Enterprises, Inc. (NYSE: NUS ... year-end 2008 financial results prior to the market opening on ... will host a conference call with the investment community later ... the call, participants can expect to hear management review past ...
Cached Medicine News:Health News:USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract 2Health News:Hearing Aids Offer Hope for Those Who Suffer from Persistent 'Ringing in the Ears,' Better Hearing Institute Survey Finds 2Health News:Hearing Aids Offer Hope for Those Who Suffer from Persistent 'Ringing in the Ears,' Better Hearing Institute Survey Finds 3Health News:Hearing Aids Offer Hope for Those Who Suffer from Persistent 'Ringing in the Ears,' Better Hearing Institute Survey Finds 4Health News:Decide for Me When I Can't, Most People Say 2Health News:Victor Dragon Joins Health Integrated to Lead Solutions Group 2Health News:UC Davis study links smoking with most male cancer deaths 2
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug ... treatment of Major Depressive Disorder in adult patients who have ... the current episode. TMS is a non-invasive technique for stimulating ... patients suffering from Major Depressive Disorder. The procedure has been ...
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... Therapeutics,(OTC Bulletin Board: ECTE) today announced positive ... Transdermal Continuous Glucose Monitoring (tCGM),System in patients ... Echo,s non-invasive,Symphony tCGM System consists of its ... Prelude(TM) SkinPrep System, which,incorporates leading-edge, needle-free skin ...
... TRIANGLE PARK, N.C., July 27 Timothy Mastro,MD, ... on August 1st,as Senior Director of Research, will ... for HIV prevention at the,International AIDS Conference in ... Prophylaxis: Current,and Planned Trials," will examine ongoing and ...
Cached Medicine Technology:Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: